메뉴 건너뛰기




Volumn 11, Issue 1, 2016, Pages 1921-1928

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE2SPOND rationale and study design

Author keywords

Exacerbation; ICS LABA; Methodology; Phosphodiesterase 4; RE2SPOND; Study design

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYCLOPROPANE DERIVATIVE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; PHOSPHODIESTERASE IV INHIBITOR;

EID: 84983541167     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S109661     Document Type: Article
Times cited : (6)

References (27)
  • 1
    • 84890686350 scopus 로고    scopus 로고
    • Roflumilast: The new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD
    • Tashkin DP. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother. 2014;15(1):85–96.
    • (2014) Expert Opin Pharmacother , vol.15 , Issue.1 , pp. 85-96
    • Tashkin, D.P.1
  • 2
    • 77953105482 scopus 로고    scopus 로고
    • The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
    • Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235–256.
    • (2010) Pulm Pharmacol Ther , vol.23 , Issue.4 , pp. 235-256
    • Hatzelmann, A.1    Morcillo, E.J.2    Lungarella, G.3
  • 4
    • 84920717687 scopus 로고    scopus 로고
    • Total and state-specific medical and absenteeism costs of COPD among adults aged $ 18 years in the United States for 2010 and projections through 2020
    • Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged $ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45.
    • (2015) Chest , vol.147 , Issue.1 , pp. 31-45
    • Ford, E.S.1    Murphy, L.B.2    Khavjou, O.3    Giles, W.H.4    Holt, J.B.5    Croft, J.B.6
  • 5
    • 37349010640 scopus 로고    scopus 로고
    • Systemic inflammation in chronic obstructive pulmonary disease: The role of exacerbations
    • Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007;4(8):626–634.
    • (2007) Proc am Thorac Soc , vol.4 , Issue.8 , pp. 626-634
    • Wouters, E.F.1    Groenewegen, K.H.2    Dentener, M.A.3    Vernooy, J.H.4
  • 6
    • 79956069263 scopus 로고    scopus 로고
    • Incremental third-party costs associated with COPD exacerbations: A retrospective claims analysis
    • Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011;14(3):315–323.
    • (2011) J Med Econ , vol.14 , Issue.3 , pp. 315-323
    • Yu, A.P.1    Yang, H.2    Wu, E.Q.3    Setyawan, J.4    Mocarski, M.5    Blum, S.6
  • 7
    • 84887909801 scopus 로고    scopus 로고
    • Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease
    • Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181.
    • (2013) BMC Med , vol.11 , pp. 181
    • Wedzicha, J.A.1    Brill, S.E.2    Allinson, J.P.3    Donaldson, G.C.4
  • 8
    • 36749063803 scopus 로고    scopus 로고
    • Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
    • Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081–1087.
    • (2007) Thorax , vol.62 , Issue.12 , pp. 1081-1087
    • Grootendorst, D.C.1    Gauw, S.A.2    Verhoosel, R.M.3
  • 10
    • 69149103642 scopus 로고    scopus 로고
    • M2-124 and M2-125 Study Groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials
    • Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 Study Groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–694.
    • (2009) Lancet , vol.374 , Issue.9691 , pp. 685-694
    • Calverley, P.M.1    Rabe, K.F.2    Goehring, U.M.3    Kristiansen, S.4    Fabbri, L.M.5    Martinez, F.J.6
  • 11
    • 79251588730 scopus 로고    scopus 로고
    • Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD
    • Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
    • (2011) Respir Res , vol.12 , pp. 18
    • Rennard, S.I.1    Calverley, P.M.2    Goehring, U.M.3    Bredenbroker, D.4    Martinez, F.J.5
  • 12
    • 70249112853 scopus 로고    scopus 로고
    • Wilmington, DE: AstraZeneca Pharmaceuticals LP
    • Daliresp®(roflumilast tablets). US prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
    • (2015) US Prescribing Information
  • 13
    • 69149098943 scopus 로고    scopus 로고
    • Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials
    • Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695–703.
    • (2009) Lancet , vol.374 , Issue.9691 , pp. 695-703
    • Fabbri, L.M.1    Calverley, P.M.2    Izquierdo-Alonso, J.L.3
  • 14
    • 84893727688 scopus 로고    scopus 로고
    • Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD
    • Hanania NA, Calverley PM, Dransfield MT, et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014;108(2):366–375.
    • (2014) Respir Med , vol.108 , Issue.2 , pp. 366-375
    • Hanania, N.A.1    Calverley, P.M.2    Dransfield, M.T.3
  • 15
    • 76449090268 scopus 로고    scopus 로고
    • Roflumilast in chronic obstructive pulmonary disease: Evidence from large trials
    • Cazzola M, Picciolo S, Matera MG. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. Expert Opin Pharmacother. 2010;11(3):441–449.
    • (2010) Expert Opin Pharmacother , vol.11 , Issue.3 , pp. 441-449
    • Cazzola, M.1    Picciolo, S.2    Matera, M.G.3
  • 16
    • 57049135358 scopus 로고    scopus 로고
    • Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis
    • Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(20):2407–2416
    • (2008) JAMA , vol.300 , Issue.20 , pp. 2407-2416
    • Drummond, M.B.1    Dasenbrook, E.C.2    Pitz, M.W.3    Murphy, D.J.4    Fan, E.5
  • 17
    • 84875473420 scopus 로고    scopus 로고
    • Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: A novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease
    • Moodley T, Wilson SM, Joshi T, et al. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease. Mol Pharmacol. 2013;83(4):894–906.
    • (2013) Mol Pharmacol , vol.83 , Issue.4 , pp. 894-906
    • Moodley, T.1    Wilson, S.M.2    Joshi, T.3
  • 18
    • 84924250308 scopus 로고    scopus 로고
    • Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial
    • Martinez FJ, Calverley PMA, Goehring U-M, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–866.
    • (2015) Lancet , vol.385 , Issue.9971 , pp. 857-866
    • Martinez, F.J.1    Calverley, P.2    Goehring, U.-M.3    Brose, M.4    Fabbri, L.M.5    Rabe, K.F.6
  • 20
    • 84899470468 scopus 로고    scopus 로고
    • Long-acting beta2-agonists for chronic obstructive pulmonary disease
    • Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(10):Cd010177.
    • (2013) Cochrane Database Syst Rev , vol.10
    • Kew, K.M.1    Mavergames, C.2    Walters, J.A.3
  • 21
    • 33847172367 scopus 로고    scopus 로고
    • Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    • Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
    • (2007) N Engl J Med , vol.356 , Issue.8 , pp. 775-789
    • Calverley, P.M.1    Erson, J.A.2    Celli, B.3
  • 22
    • 53749102775 scopus 로고    scopus 로고
    • A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    • Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
    • (2008) N Engl J Med , vol.359 , Issue.15 , pp. 1543-1554
    • Tashkin, D.P.1    Celli, B.2    Senn, S.3
  • 23
    • 34247561439 scopus 로고    scopus 로고
    • Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial
    • Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545–555.
    • (2007) Ann Intern Med , vol.146 , Issue.8 , pp. 545-555
    • Aaron, S.D.1    Vandemheen, K.L.2    Fergusson, D.3
  • 24
    • 84903602640 scopus 로고    scopus 로고
    • Long-acting bronchodilators in COPD: Where are we now and where are we going?
    • Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10(2):110–120.
    • (2014) Breathe , vol.10 , Issue.2 , pp. 110-120
    • Cazzola, M.1    Page, C.2
  • 25
    • 84878507499 scopus 로고    scopus 로고
    • Introducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD foundation
    • Rennard S, Thomashow B, Crapo J, et al. Introducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD foundation. COPD. 2013;10(3):378–389.
    • (2013) COPD , vol.10 , Issue.3 , pp. 378-389
    • Rennard, S.1    Thomashow, B.2    Crapo, J.3
  • 26
    • 84939464236 scopus 로고    scopus 로고
    • Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
    • Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639.
    • (2015) Lancet Respir Med , vol.3 , Issue.8 , pp. 631-639
    • Chen, W.1    Thomas, J.2    Sadatsafavi, M.3    Fitzgerald, J.M.4
  • 27
    • 84871698675 scopus 로고    scopus 로고
    • Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol
    • Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis. 2012;7:375–382
    • (2012) Int J Chron Obstruct Pulmon Dis , vol.7 , pp. 375-382
    • Calverley, P.M.1    Martinez, F.J.2    Fabbri, L.M.3    Goehring, U.M.4    Rabe, K.F.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.